Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational cohort study of eliglustat after switch from ERT or miglustat in adults with type 1 Gaucher disease
MOH_2018-11-18_004783Phase 4Not yet recruiting
- Sponsor
- Sanofi
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eliglustat in Gaucher disease type 1 (GD1), sponsored by Sanofi. Primary endpoint: Lumbar spine bone mineral density. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
eliglustat
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on MOH_2018-11-18_004783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-18_004783.